Your browser doesn't support javascript.
Efficacy and safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive and biological therapy: Prospective observational study.
Wasserbauer, Martin; Hlava, Stepan; Trojanek, Milan; Stovicek, Jan; Milota, Tomas; Drabek, Jiri; Koptová, Petra; Cupkova, Andrea; Pichlerová, Dita; Kucerova, Barbora; Coufal, Stepan; Keil, Radan.
  • Wasserbauer M; Department of Internal Medicine, 2nd Faculty of Medicine Charles University in Prague and Motol University Hospital, Prague, Czech Republic.
  • Hlava S; Department of Internal Medicine, 2nd Faculty of Medicine Charles University in Prague and Motol University Hospital, Prague, Czech Republic.
  • Trojanek M; 1st Department of Infectious Diseases, 2nd Medical Faculty Charles University in Prague and Hospital Na Bulovce, Prague, Czech Republic.
  • Stovicek J; Department of Internal Medicine, 2nd Faculty of Medicine Charles University in Prague and Motol University Hospital, Prague, Czech Republic.
  • Milota T; Department of Immunology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
  • Drabek J; Department of Internal Medicine, 2nd Faculty of Medicine Charles University in Prague and Motol University Hospital, Prague, Czech Republic.
  • Koptová P; Department of Internal Medicine, 2nd Faculty of Medicine Charles University in Prague and Motol University Hospital, Prague, Czech Republic.
  • Cupkova A; Department of Internal Medicine, 2nd Faculty of Medicine Charles University in Prague and Motol University Hospital, Prague, Czech Republic.
  • Pichlerová D; Department of Internal Medicine, 2nd Faculty of Medicine Charles University in Prague and Motol University Hospital, Prague, Czech Republic.
  • Kucerova B; Department of Pediatric Surgery, 2nd Faculty of Medicine Charles University in Prague and University Hospital Motol, Prague, Czech Republic.
  • Coufal S; Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic.
  • Keil R; Department of Internal Medicine, 2nd Faculty of Medicine Charles University in Prague and Motol University Hospital, Prague, Czech Republic.
PLoS One ; 17(9): e0273612, 2022.
Article in English | MEDLINE | ID: covidwho-2009702
ABSTRACT
BACKGROUND AND

AIMS:

SARS-CoV-2 is a worldwide serious health problem and vaccination seems to have a crucial role in managing the COVID-19 pandemic. The aim of this prospective observational study was to monitor the trend of antibodies against SARS-CoV-2 after vaccination with BNT162b2 (COMIRNATY) in patients with inflammatory bowel disease treated by immunosuppressive and/or biological therapy, demonstrate whether any type of this therapy is associated with poorer production of antibodies against COVID-19 and evaluate the safety of vaccination against COVID-19 in these patients.

METHODS:

Eighty-seven eligible patients from one tertiary gastroenterological center with inflammatory bowel disease (60 with CD, 27 with UC) treated by immunosuppressive and/or biological therapy from the antiTNFα group were indicated to vaccination against SARS-CoV-2. Effectiveness of vaccination was evaluated by the values of antibodies before and 4 weeks after 2nd dose of vaccine. Additional goal was to evaluate adverse events of vaccination.

RESULTS:

Before the 2nd dose of vaccine, geometric mean of SARS-CoV-2 IgG antibodies were 40.7 U/ml in the biological therapy group, 34.8 U/ml in the azathioprine group and 44.8 U/ml in the combination therapy group of patients. The geometric means were 676.5.7 U/ml in the biological therapy group, 614.4 U/ml in the azathioprine group and 500.1 U/ml in the combination therapy group of patients four weeks after 2nd dose. Statistically significant differences between these groups were not proved. Several non-severe local and general adverse events were present in our patients with a majority of these events on the day of vaccine administration and the day after, no anaphylactic reactions were present.

CONCLUSIONS:

Our measurements proved the efficacy and safety of vaccination against SARS-CoV-2 in patients with inflammatory bowel disease treated by immunosuppressive and/or biological therapy. Statistically significant differences between our groups of patients were not proved.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / Inflammatory Bowel Diseases / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2022 Document Type: Article Affiliation country: Journal.pone.0273612

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / Inflammatory Bowel Diseases / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2022 Document Type: Article Affiliation country: Journal.pone.0273612